Article
Pharmacology & Pharmacy
Donna S. Cox, Muhammad Rehman, Tahira Khan, Katherine Ginman, Joanne Salageanu, Robert R. LaBadie, Katty Wan, Bharat Damle
Summary: This study aimed to evaluate the pharmacokinetics (PK) and safety of coadministration of nirmatrelvir/ritonavir or ritonavir alone with midazolam and dabigatran, two commonly used drugs. The results showed that coadministration with nirmatrelvir /ritonavir or ritonavir alone significantly increased the exposure of midazolam and dabigatran. However, the exposure of midazolam was comparable between nirmatrelvir/ritonavir and ritonavir alone, suggesting that nirmatrelvir had no additional effect. The slightly higher dabigatran exposure when coadministered with nirmatrelvir/ritonavir compared to ritonavir alone indicated a minor incremental effect of nirmatrelvir.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Immunology
Kan Chen, Xiaoduo Guan, Zhenfan Yang, Yue Zhou, Ziyi Liu, Xueyuan Deng, Donghong Liu, Pei Hu, Rui Chen
Summary: The objectives of the two studies were to compare the pharmacokinetics, safety, and tolerability of golidocitinib in healthy Chinese participants to Western participants, as well as the effect of food on its bioavailability. The results showed slight inter-ethnic differences in pharmacokinetic parameters, but they were not considered clinically relevant. Food had a minor effect on the bioavailability of golidocitinib. Hence, the data supported using the same dose and regimen for multinational clinical development.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Medicinal
Moon Hee Lee, Seok-Kyu Yoon, Hyungsub Kim, Yong-Soon Cho, Sungpil Han, Shi Hyang Lee, Kyun-Seop Bae, Jina Jung, Sung Hee Hong, Hyeong-Seok Lim
Summary: This study aimed to examine the pharmacokinetic interactions between bazedoxifene and cholecalciferol and the tolerability of their combined administration in healthy male subjects. The results showed that this combined therapy was well tolerated at the dose levels used in the study, and there was a mild degree of pharmacokinetic interaction.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Pharmacology & Pharmacy
JungJin Oh, Eunsol Yang, In-Jin Jang, Hyejung Lee, Hokyun Yoo, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh
Summary: This study aimed to evaluate the pharmacodynamic and pharmacokinetic interactions between aspirin and fexuprazan in healthy Koreans. The results showed that the combination of fexuprazan and aspirin had no significant effect on platelet aggregation inhibitory activity and systemic exposure to aspirin. This finding suggests the potential of fexuprazan for the prevention of aspirin-induced gastrointestinal complications.
Article
Multidisciplinary Sciences
Ali Jaber, Israa Al-Ani, Mohammad Hailat, Enas Daoud, Anmar Abu-Rumman, Zainab Zakaraya, Bashar J. M. Majeed, Osaid Al Meanazel, Wael Abu Dayyih
Summary: This study investigates the effects of simultaneous administration of esomeprazole and apixaban in rats, as well as their pharmacokinetics and potential interactions. The results show that the combination of these drugs affects their pharmacokinetics, with an increase in apixaban's concentration and area under the curve (AUC), a decrease in esomeprazole's concentration and AUC, and a decrease in bioavailability when both drugs are taken together.
Article
Chemistry, Medicinal
Duanduan Cong, Wenyuan Qi, Xiaohui Liu, Xiaoyu Xu, Lingyun Dong, Wei Xue, Kexin Li
Summary: This study aimed to compare the pharmacokinetic characteristics of enteric-coated sustained-release (EcSr) aspirin tablets with enteric-coated (Ec) aspirin tablets in healthy Chinese participants. The results showed that EcSr aspirin tablets had less inter-individual variation in release and absorption, and meals had no significant effect on their pharmacokinetics.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Clinical Neurology
Benjamin Berger, Ruediger Kornberger, Jasper Dingemanse
Summary: The study investigated the pharmacokinetic and pharmacodynamic interactions between daridorexant and citalopram in healthy subjects, showing no relevant effects on exposure levels between the two drugs. Co-administration with citalopram at steady state led to changes in pharmacodynamic assessments, while doses up to 50 mg of daridorexant were found to be safe when used concomitantly with citalopram.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2021)
Review
Neurosciences
Gaetano Zaccara, Valentina Franco
Summary: Antiseizure medications and drugs for psychiatric diseases often interact at a metabolic level, primarily through changes in the activity of cytochrome P450 enzymes. Some antiseizure medications can reduce the plasma concentrations of certain antidepressants, antipsychotics, and benzodiazepines, while newer antiseizure medications have a lower potential for these interactions. However, some newer antidepressants may inhibit CYP enzymes and increase the serum concentrations of certain antiseizure medications. Knowledge of specific CYP enzymes involved in the metabolism of individual medications and the influence of comedication on the activity of these enzymes can help anticipate clinically relevant interactions. Careful evaluation of clinical response and personalized dosage adjustments based on drug serum concentrations are recommended to manage these interactions.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Sumit Bansal, C. Austin Zamarripa, Tory R. Spindle, Elise M. Weerts, Kenneth E. Thummel, Ryan Vandrey, Mary F. Paine, Jashvant D. Unadkat
Summary: Understanding the interactions between cannabis and drugs is crucial in light of increased access and use of cannabis due to regulatory changes. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) are potent inhibitors of certain cytochrome P450 (CYP) enzymes. In this study, the potential pharmacokinetic interactions between cannabis extracts and common drugs were evaluated in healthy adults. The results showed that the CBD + Δ9-THC brownie significantly inhibited the activity of CYP2C19, CYP2C9, CYP3A, and CYP1A2 enzymes, while the Δ9-THC brownie did not inhibit any CYP enzymes. The findings can guide dose adjustments of drugs co-administered with cannabis products to minimize the risk of interactions with Δ9-THC.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Pharmacology & Pharmacy
Seol Ju Moon, Naree Shin, MinJa Kang, Bongtae Kim, Min-Gul Kim
Summary: This study evaluated the pharmacokinetic interaction between tegoprazan and commonly used NSAIDs, including naproxen, aceclofenac, and celecoxib. The results showed minimal interaction between tegoprazan and these NSAIDs within the administered dose and time range.
CLINICAL THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Seol Ju Moon, Naree Shin, MinJa Kang, Bongtae Kim, Min-Gul Kim
Summary: This study aimed to evaluate the pharmacokinetic interaction between tegoprazan and commonly used NSAIDs, namely naproxen, aceclofenac, and celecoxib. The results showed that tegoprazan pharmacokinetic parameters did not change significantly in all groups, while there were some fluctuations in the parameters of naproxen, aceclofenac, and celecoxib.
CLINICAL THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Yanjun Cui, Ying Li, Caihui Guo, Yajing Li, Yinling Ma, Zhanjun Dong
Summary: This study investigated the pharmacokinetic drug interactions between canagliflozin and sorafenib or lenvatinib and found significant changes in the plasma concentrations and apparent clearance of these drugs. These findings provide a reference for the use of canagliflozin, sorafenib and lenvatinib in patients with HCC and T2DM.
Article
Oncology
Kunhong Deng, Yi Zou, Chan Zou, Hong Wang, Yuxia Xiang, Xiaoyan Yang, Shuang Yang, Chang Cui, Guoping Yang, Jie Huang
Summary: This study aimed to investigate the pharmacokinetic characteristics and safety of the combination of the strong CYP3A4-metabolizing enzyme inhibitor itraconazole and the novel oral Enhancer of Zeste Homolog 2 inhibitor SHR2554. The results showed that the combination of itraconazole and SHR2554 significantly increased the plasma concentration of SHR2554. The combination regimen was well tolerated and had a good safety profile.
Article
Pharmacology & Pharmacy
Adedayo Adedoyin, Craig Fancourt, Karsten Menzel, Tian Zhao, Charles Tomek, Deborah Panebianco, Jacqueline B. McCrea, S. Aubrey Stoch, Marian Iwamoto
Summary: The study confirmed the safety of coadministration of fluconazole and letermovir, with no significant changes in pharmacokinetic parameters.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
(2021)
Article
Medicine, Research & Experimental
Orestis Papasouliotis, David Mitchell, Pascal Girard, Martin Dyroff
Summary: This study aimed to develop pharmacokinetic and pharmacodynamic models of the BTK inhibitor Evobrutinib in the treatment of multiple sclerosis and simulate its effects under different dosing regimens. The results suggest that Evobrutinib doses of 25 mg once-daily, 50 mg twice-daily, or 75 mg twice-daily are possible choices for further development.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2022)